Выходит 6 номеров в год
ISSN Печать: 1045-4403
ISSN Онлайн: 2162-6502
Indexed in
Aberrant Regulation of Alternative Pre-mRNA Splicing in Hepatocellular Carcinoma
Краткое описание
Alternative splicing of precursors messenger RNA (pre-mRNA) is commonly used to increase the diversity of messenger RNAs expressed by the genome in normal multicellular organisms. Dysregulation of alternative splicing underlies a number of human diseases, including cancers. Increasing evidence supports the important role of this expansive layer of gene regulation in hepatocarcinogenesis. Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide because of its aggressive property and limited therapeutic options. Studies suggest that aberrant alternative splicing promotes generation of oncogenic variants in HCC, whereas tumor suppressors are self-inactivated by aberrant alternative splicing in HCC. Moreover, different spliced variants of the same gene can display distinct and even antagonistic biological functions in HCC. As a result, inhibiting the splicing of oncogenic variants and the self-inactivation of tumor suppressors are likely to be new therapy strategies. This review provides a perspective of the emerging evidence of both alternative splicing as a critical mechanism for the development of HCC and that potential cross-talk through signaling pathways among different variants might aid in the development of novel molecular targets of HCC.
-
Liu Li-Juan, Xie Shui-Xiang, Chen Ya-Tang, Xue Jing-Ling, Zhang Chuan-Jie, Zhu Fan, Aberrant regulation of Wnt signaling in hepatocellular carcinoma, World Journal of Gastroenterology, 22, 33, 2016. Crossref
-
Krivtsova Olga, Makarova Anna, Lazarevich Natalia, Aberrant expression of alternative isoforms of transcription factors in hepatocellular carcinoma, World Journal of Hepatology, 10, 10, 2018. Crossref
-
Jin Young-Joo, Byun Seyoun, Han Seonggyun, Chamberlin John, Kim Dongwook, Kim Min Jung, Lee Younghee, Differential alternative splicing regulation among hepatocellular carcinoma with different risk factors, BMC Medical Genomics, 12, S8, 2019. Crossref
-
Liu Lijuan, Liu Youyi, Chen Xiaobei, Wang Miao, Zhou Yan, Zhou Ping, Li Wenxin, Zhu Fan, Variant 2 of KIAA0101, antagonizing its oncogenic variant 1, might be a potential therapeutic strategy in hepatocellular carcinoma, Oncotarget, 8, 27, 2017. Crossref
-
Yosudjai Juthamas , Wongkham Sopit , Jirawatnotai Siwanon , Kaewkong Worasak , Aberrant mRNA splicing generates oncogenic RNA isoforms and contributes to the development and progression of cholangiocarcinoma (Review), Biomedical Reports, 2019. Crossref
-
Wu Panyisha, Zhang Moya, Webster Nicholas J. G., Alternative RNA Splicing in Fatty Liver Disease, Frontiers in Endocrinology, 12, 2021. Crossref
-
Xu Rui-Yao, Ding Zhan, Zhao Qing, Ke Tiao-Ying, Chen Shu, Wang Xing-Yu, Wang Yao-Yun, Sheng Meng-Fei, Wang Wei, Long Ni, Shen Yu-Xian, Xu Yong-Zhen, Shao Wei, An Alternatively Spliced Variant of METTL3 Mediates Tumor Suppression in Hepatocellular Carcinoma, Genes, 13, 4, 2022. Crossref
-
Shaglouf Laila H. Faraj, Ranjpour Maryam, Wajid Saima, Tandon Rakesh, Vasudevan Karisangal Ramaswamy, Jain Swatantra Kumar, Elevated expression of ISY1, APOA-1, SYNE1, MTG1, and MMP10 at HCC initiation: HCC specific protein network involving interactions of key regulators of lipid metabolism, EGFR signaling, MAPK, and splicing pathways, Protoplasma, 2022. Crossref
-
Lu Yu, Ren Xuechen, Zhou Chengliang, Chen Hao, Fan Yong, Wang Chen, Overexpression of Ribosomal Protein S6 Kinase A4 (RPS6KA4) Predicts a Poor Prognosis in Hepatocellular Carcinoma Patients: A Study Based on TCGA Samples, Combinatorial Chemistry & High Throughput Screening, 25, 13, 2022. Crossref